Press Releases May 13, 2026 12:00 PM

GAMCO Natural Resources, Gold & Income Trust Declares Monthly Distributions of $0.06 Per Share

GAMCO Natural Resources, Gold & Income Trust declares monthly distributions of $0.06 per share with a 20% annual increase in total distributions for 2026.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
GNT

The Board of Trustees of GAMCO Natural Resources, Gold & Income Trust (NYSE:GNT) approved monthly cash distributions of $0.06 per share for July through September 2026, continuing their policy of paying monthly distributions. The annual distribution was increased by 20% to $0.72 per share, paid monthly. Distributions in 2026 are expected to primarily constitute a return of capital for tax purposes. The Fund employs covered call strategies and invests in gold and natural resources equities to generate income.

GAMCO Natural Resources, Gold & Income Trust Declares Monthly Distributions of $0.06 Per Share
GNT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Monthly cash distributions of $0.06 per share declared for July-September 2026.
  • Annual distribution increased by 20% to $0.72 per share, reflecting confidence in income generation.
  • Fund primarily invests in gold and natural resources equities with a covered call option strategy to generate income.
  • The Fund's distributions in 2026 are expected to be primarily a return of capital, affecting tax treatment for shareholders.

RYE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The Board of Trustees of GAMCO Natural Resources, Gold & Income Trust (NYSE:GNT) (the “Fund”) approved the continuation of its policy of paying monthly cash distributions. The Board of Trustees declared cash distributions of $0.06 per share for each of July, August, and September 2026. Based on current dynamics, the Fund may make distributions in excess of the Fund’s earnings. It is currently expected that distributions to common shareholders in 2026 will primarily constitute a return of capital for tax purposes.

The Board of Trustees increased the annual distribution 20% to $0.72 per share, which will be paid $0.06 per share monthly, commencing with the January 2026 monthly distribution.

Distribution MonthRecord DatePayable DateDistribution Per ShareJulyJuly 17, 2026July 24, 2026$0.06AugustAugust 17, 2026August 24, 2026$0.06SeptemberSeptember 16, 2026September 23, 2026$0.06


Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

Because the Fund’s current monthly distributions are subject to modification by the Board of Trustees at any time and the Fund’s income will fluctuate, there can be no assurance that the Fund will pay distributions at a particular rate or frequency.   Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution.

Short-term capital gains, qualified dividend income, ordinary income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. There are no capital loss carryforwards for book purposes. Therefore the Fund, on a book basis, may be distributing short term gains generated from option premiums that will not be taxable in 2026 because of the capital loss carryforwards available on a tax basis. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2026 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2026 distributions in early 2027 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund’s distribution policy and other information about the Fund, call:

David Schachter
(914) 921-5057

The Fund’s NAV per share will fluctuate with changes in the market value of the Fund’s portfolio securities. Stocks are subject to market, economic, and business risks that cause their prices to fluctuate. Investors acquire shares of the Fund on a securities exchange at market value, which fluctuates according to the dynamics of supply and demand. When Fund shares are sold, they may be worth more or less than their original cost. Consequently, you can lose money by investing in the Fund.

Covered Call and Other Option Transaction Risks. There are several risks associated with writing covered calls and entering into other types of option transactions. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, resulting in a given transaction not achieving its objectives. In addition, a decision as to whether, when, and how to use covered call options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful because of market behavior or unexpected events. As the writer of a covered call option, the Fund forgoes, during the option’s life, the opportunity to profit from increases in the market value of the security covering the call option above the exercise price of the call option, but has retained the risk of loss should the price of the underlying security decline.

About The GAMCO Natural Resources, Gold & Income Trust
The GAMCO Natural Resources, Gold & Income Trust is a diversified, closed-end management investment company with $168 million in total net assets whose primary investment objective is to provide a high level of current income. The Fund invests primarily in equity securities of gold and natural resources companies and intends to earn income primarily through a strategy of writing (selling) primarily covered call options on equity securities in its portfolio. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI).

NYSE – GNT
CUSIP – 36465E101

Investor Relations Contact:
David Schachter
(914) 921-5057 dschachter@gabelli.com


Risks

  • Distributions may exceed earnings and are subject to modification depending on market conditions, potentially impacting income stability for investors.
  • Covered call strategies involve risks including loss of potential gains and market price declines, posing risks to fund performance.
  • The Fund's NAV fluctuates with market value changes of portfolio securities and options, exposing shareholders to market, economic, and business risks.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026